Jonathan Dau is a Rheumatology/Immunology physician. OpenAlex indexes 15 publications with 1,658 citations (h-index 7).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
510 Superior Ave Ste 200d
Newport Beach, CA 926633664
Telephone
949-791-3001Provider last certified this registry record 27 Feb 2024.
Industry payments
29 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- SOBI, INCProgram year20257 payments
- Novartis Pharmaceuticals CorporationProgram year202518 payments
- ABBVIE INC.Program year202523 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
56.3%Corticosteroid56.3%Methylprednisolone acetate97%Methylprednisolone3%Part D + Part B≥14 patientsMetabolism & gastrointestinal
17.5%Corticosteroid16.1%Prednisone100%Part D≥78 patientsAntidiarrheal microorganisms1.4%Folic Acid100%Part D≥11 patientsCancer & immunology
8%Folate Analog Metabolic Inhibitor4.8%Methotrexate100%Part D≥31 patientsAntirheumatic Agent1.6%Leflunomide100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The 2023 ACR/<scp>EULAR</scp> Classification Criteria for Calcium Pyrophosphate Deposition Disease
Arthritis & Rheumatology
2023 - The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease
Annals of the Rheumatic Diseases
2023
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”